Relapse after First-Line Fixed Duration Ibrutinib plus Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

被引：0

作者：

Ghia, Paolo ^{[1
,2
]}

Wierda, William G. ^{[3
]}

Barr, Paul M. ^{[4
]}

Kipps, Thomas J. ^{[5
]}

Siddiqi, Tanya ^{[6
]}

Allan, John N. ^{[7
]}

Hunter, Zoe ^{[8
]}

Zhou, Cathy ^{[8
]}

Szoke, Anita ^{[8
]}

Dean, James P. ^{[9
,10
]}

Tam, Constantine S. ^{[11
,12
]}

机构：

[1] Univ Vita Salute San Raffaele, Milan, Italy

[2] IRCCS Osped San Raffaele, Milan, Italy

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY USA

[5] UC San Diego Moores Canc Ctr, Duarte, CA USA

[6] City Hope Natl Med Ctr, Duarte, CA USA

[7] Weill Cornell Med, Long Isl City, NY USA

[8] AbbVie, N Chicago, IL USA

[9] AbbVie, IMBRUVICA, N Chicago, IL USA

[10] AbbVie, Pediat Oncol, N Chicago, IL USA

[11] Alfred Hosp, Melbourne, Vic, Australia

[12] Monash Univ, Melbourne, Vic, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187128

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Ibrutinib for First-Line Treatment of Chronic Lymphocytic Leukemia in Patients Aged ≥65 Years: Results With 5 Years of Follow-Up for the RESONATE-2 Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 14 - 16
[32] LONG-TERM FOLLOW-UP OF SINGLE-AGENT IBRUTINIB IN FIRST-LINE AND RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Reid, Mark
Settlemire, Jillian
Liu, Emily
Amaya-Chanaga, Carlos
Coutre, Steven
Byrd, John
ONCOLOGY NURSING FORUM, 2019, 46 (02)
[33] Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
Burger, Jan A.
Robak, Tadeusz
Demirkan, Fatih
Bairey, Osnat
Moreno, Carol
Simpson, David
Munir, Talha
Stevens, Don A.
Dai, Sandra
Cheung, Leo W. K.
Kwei, Kevin
Lal, Indu
Hsu, Emily
Kipps, Thomas J.
Tedeschi, Alessandra
LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1375 - 1386
[34] Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia
Burger, Jan
Tedeschi, Alessandra
Barr, Paul M.
Robak, Tadeusz
Owen, Carolyn
Ghia, Paolo
Bairey, Osnat
Hillmen, Peter
Coutre, Steven E.
Devereux, Stephen
Grosicki, Sebastian
McCarthy, Helen
Li, Jianyong
Simpson, David
Offner, Fritz
Moreno, Carol
Dai, Sandra
Lal, Indu
Dean, James P.
Kipps, Thomas J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S274 - S274
[35] Characterization and Outcomes of the Spanish Patients Included in the GLOW and CAPTIVATE-FD Studies: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Abrisqueta, Pau
Lopez-Jimenez, Javier
Osorio, Santiago
Hernandez Rivas, Jose Angel
de la Cruz, Fatima
Magnano, Laura
Maria Arguinano, Jose
Gonzalez, Marcos
de la Serna, Javier
Szoke, Anita
Neumayr, Lynne D.
Diels, Joris
Schioppa, Claudio A.
Rubio Azpeitia, Eva
Dominguez-Lubillo, Teresa
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S359 - S359
[36] Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Munir, Talha
Brown, Jennifer R.
O'Brien, Susan
Barrientos, Jacqueline C.
Barr, Paul M.
Reddy, Nishitha M.
Coutre, Steven
Tam, Constantine S.
Mulligan, Stephen P.
Jaeger, Ulrich
Kipps, Thomas J.
Moreno, Carol
Montillo, Marco
Burger, Jan A.
Byrd, John C.
Hillmen, Peter
Dai, Sandra
Szoke, Anita
Dean, James P.
Woyach, Jennifer A.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (12) : 1353 - 1363
[37] Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration (Placebo) Treatment Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
Tam, C. S.
Allan, J. N.
Siddiqi, T.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 8 - 9
[38] Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
Allan, John N.
Siddiqi, Tanya
Kipps, Thomas J.
Kuss, Bryone J.
Badoux, Xavier C.
Barrientos, Jacqueline C.
Tedeschi, Alessandra
Opat, Stephen
Flinn, Ian W.
Barca, Eva Gonzalez
Jacobs, Ryan
Szafer-Glusman, Edith
Zhou, Cathy
Szoke, Anita
Wierda, William G.
Ghia, Paolo
Tam, Constantine S.
BLOOD, 2022, 140
[39] Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: 1-Year Disease-Free Survival Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 14 - 15
[40] REAL-WORLD ECONOMIC OUTCOMES OF FIRST-LINE (1L) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
Challagulla, S.
Lee, P.
Kistler, K.
Douyon, L.
Lai, D.
Iyengar, R.
VALUE IN HEALTH, 2021, 24 : S38 - S38

← 1 2 3 4 5 →